NCT00511667View on ClinicalTrials.gov

A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MK0941

MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day

DRUG

Comparator: Placebo

Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00511667 - A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005) | Biotech Hunter | Biotech Hunter